MA33743B1 - Compositions comprenant du tramadol et du célécoxib dans le traitement de la douleur - Google Patents

Compositions comprenant du tramadol et du célécoxib dans le traitement de la douleur

Info

Publication number
MA33743B1
MA33743B1 MA34860A MA34860A MA33743B1 MA 33743 B1 MA33743 B1 MA 33743B1 MA 34860 A MA34860 A MA 34860A MA 34860 A MA34860 A MA 34860A MA 33743 B1 MA33743 B1 MA 33743B1
Authority
MA
Morocco
Prior art keywords
tramadol
celecoxib
treatment
pain
combinations
Prior art date
Application number
MA34860A
Other languages
Arabic (ar)
English (en)
Inventor
Salido Enrique Portillo
Ces Sebasti Videla
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41566149&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33743(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA33743B1 publication Critical patent/MA33743B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques comprenant du tramadol et du célécoxib et leurs utilisations en tant que médicaments ou analgésiques, plus particulièrement pour le traitement de fortes douleurs afin de modérer celles-ci au moyen d'un composant pour l'inflammation.
MA34860A 2009-10-16 2012-05-11 Compositions comprenant du tramadol et du célécoxib dans le traitement de la douleur MA33743B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09384004A EP2311446A1 (fr) 2009-10-16 2009-10-16 Compositions comprenant du Tramadol et du Célécoxib pour le traitement de la douleur
PCT/EP2010/006317 WO2011045075A1 (fr) 2009-10-16 2010-10-15 Compositions comprenant du tramadol et du célécoxib dans le traitement de la douleur

Publications (1)

Publication Number Publication Date
MA33743B1 true MA33743B1 (fr) 2012-11-01

Family

ID=41566149

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34860A MA33743B1 (fr) 2009-10-16 2012-05-11 Compositions comprenant du tramadol et du célécoxib dans le traitement de la douleur

Country Status (33)

Country Link
US (3) US8569271B2 (fr)
EP (3) EP2311446A1 (fr)
JP (2) JP5579858B2 (fr)
KR (1) KR101688996B1 (fr)
CN (2) CN107050006A (fr)
AR (1) AR078653A1 (fr)
AU (1) AU2010306114B2 (fr)
BR (1) BR112012005044B8 (fr)
CA (1) CA2771651C (fr)
CO (1) CO6511249A2 (fr)
CY (1) CY1114960T1 (fr)
DK (1) DK2488170T3 (fr)
EC (1) ECSP12011735A (fr)
ES (1) ES2450615T3 (fr)
HR (1) HRP20140157T1 (fr)
IL (1) IL218096A (fr)
IN (1) IN2012DN01434A (fr)
MA (1) MA33743B1 (fr)
MX (1) MX2012003051A (fr)
MY (1) MY156275A (fr)
NZ (1) NZ598361A (fr)
PL (1) PL2488170T3 (fr)
PT (1) PT2488170E (fr)
RS (1) RS53202B (fr)
RU (2) RU2707752C2 (fr)
SG (1) SG178833A1 (fr)
SI (1) SI2488170T1 (fr)
SM (1) SMT201400035B (fr)
TN (1) TN2012000059A1 (fr)
TW (1) TWI466668B (fr)
UA (1) UA108213C2 (fr)
WO (1) WO2011045075A1 (fr)
ZA (1) ZA201202151B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2177215A1 (fr) 2008-10-17 2010-04-21 Laboratorios Del. Dr. Esteve, S.A. Co-cristaux de tramadol et NSAID
US8746719B2 (en) * 2010-08-03 2014-06-10 Polaris Industries Inc. Side-by-side vehicle
WO2012136969A2 (fr) * 2011-04-05 2012-10-11 Anant Sharma Traitements ophtalmiques
PL2811833T3 (pl) 2012-02-06 2016-05-31 William L Pridgen Połączenie famcyklowiru i celekoksybu na czynnościowe zespoły somatyczne
WO2016116942A1 (fr) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Nouveaux composés pharmaceutiques comprenant du ticagrélor avec des sels d'aspirine
RU2708254C2 (ru) * 2015-05-28 2019-12-05 Др. Редди'С Лабораториз Лтд. Пероральная композиция целекоксиба для лечения боли
KR101710792B1 (ko) * 2015-07-14 2017-02-28 주식회사 유영제약 세레콕시브 및 트라마돌을 함유하는 약제학적 조성물
MX2016006464A (es) * 2016-05-18 2017-11-17 Laboratorios Liomont S A De C V Composicion farmaceutica de una combinacion de clorhidrato de tramadol-etoricoxib para el tratamiento del dolor.
BR112018074486A2 (pt) * 2016-05-27 2019-05-28 Dr Reddy´S Laboratories Ltd composição oral de celecoxib para tratamento da dor
WO2018186650A2 (fr) * 2017-04-03 2018-10-11 주식회사 킴스헬스케어 Comprimé composite double pour administration orale contenant du tramadol et du célécoxib
US20200323780A1 (en) 2017-04-03 2020-10-15 Kims Healthcare Co., Ltd. Bilayer combination tablet for oral administration containing tramadol and celecoxib
KR102631399B1 (ko) 2018-03-30 2024-02-01 씨지인바이츠 주식회사 폴마콕시브 및 프레가발린을 포함하는 통증 치료용 약제학적 조성물
BR112021020893A2 (pt) * 2019-05-14 2022-04-19 Esteve Pharmaceuticals Sa Uso de cocristais de tramadol e celecoxib para o tratamento de dor, ao mesmo tempo que reduzindo a suscetibilidade a abuso do tramadol
CN112007024A (zh) * 2019-05-28 2020-12-01 江苏恒瑞医药股份有限公司 艾瑞昔布与曲马多联合在制备治疗疼痛的药物中的用途
CN114681470A (zh) 2020-12-28 2022-07-01 雷迪博士实验室有限公司 治疗疼痛的方法
WO2025125888A1 (fr) * 2023-12-15 2025-06-19 Centro De Investigación Y De Estudios Avanzados Del I.P.N. Compositions d'aripiprazole et de tramadol ayant des effets de potentialisation et une efficacité analgésique élevée utiles pour le traitement de la douleur neuropathique

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU661723B2 (en) 1991-10-30 1995-08-03 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
US5516803A (en) 1991-10-30 1996-05-14 Mcneilab, Inc. Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
MXPA01008903A (es) * 1999-03-01 2003-07-21 Johnson & Jonhson Composicion que comprende un material de tramadol y un farmaco inhibidor de cox-2 selectivo.
DE19927688A1 (de) 1999-06-17 2000-12-21 Gruenenthal Gmbh Mehrschichttablette zur Verabreichung einer fixen Kombination von Tramadol und Diclofenac
US7790905B2 (en) * 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
NZ535500A (en) * 2002-02-19 2006-09-29 Adcock Ingram Ltd Pharmaceutical combinations of COX-2 inhibitors i.e. meloxicam, opiates i.e. codeine and centrally acting cox inhibitors i.e. paracetamol
US20080031950A1 (en) * 2007-04-27 2008-02-07 Nectid Inc. Novel anelgesic combination
CN104817501B (zh) * 2009-10-16 2017-09-22 埃斯蒂文博士实验室股份有限公司 曲马多与昔布类的共晶体
EP2392319A1 (fr) * 2010-06-04 2011-12-07 Laboratorios Del. Dr. Esteve, S.A. Composition pharmaceutique contenant des co-cristaux de tramadol et d'un coxib

Also Published As

Publication number Publication date
CY1114960T1 (el) 2016-12-14
EP2311446A1 (fr) 2011-04-20
TN2012000059A1 (en) 2013-09-19
JP5579858B2 (ja) 2014-08-27
EP2737898A1 (fr) 2014-06-04
AU2010306114B2 (en) 2015-07-23
TW201114418A (en) 2011-05-01
CN107050006A (zh) 2017-08-18
CA2771651C (fr) 2016-08-23
TWI466668B (zh) 2015-01-01
RU2012120087A (ru) 2013-11-27
DK2488170T3 (en) 2014-03-03
PT2488170E (pt) 2014-03-11
BR112012005044B8 (pt) 2021-05-25
IL218096A (en) 2015-02-26
CN102573824A (zh) 2012-07-11
BR112012005044B1 (pt) 2020-12-15
US20120172341A1 (en) 2012-07-05
EP2488170B1 (fr) 2014-01-22
UA108213C2 (uk) 2015-04-10
IN2012DN01434A (fr) 2015-06-05
JP2014221797A (ja) 2014-11-27
AU2010306114A1 (en) 2012-03-15
CA2771651A1 (fr) 2011-04-11
US8569271B2 (en) 2013-10-29
KR101688996B1 (ko) 2016-12-22
US20140024622A1 (en) 2014-01-23
NZ598361A (en) 2014-01-31
EP2488170A1 (fr) 2012-08-22
ZA201202151B (en) 2012-11-28
WO2011045075A1 (fr) 2011-04-21
MX2012003051A (es) 2012-05-29
MY156275A (en) 2016-01-29
RU2016125895A3 (fr) 2018-12-05
ES2450615T3 (es) 2014-03-25
PL2488170T3 (pl) 2014-05-30
HK1173379A1 (en) 2013-05-16
SG178833A1 (en) 2012-05-30
KR20120089287A (ko) 2012-08-09
RU2707752C2 (ru) 2019-11-29
AR078653A1 (es) 2011-11-23
JP2013507408A (ja) 2013-03-04
IL218096A0 (en) 2012-04-30
SMT201400035B (it) 2014-05-07
ECSP12011735A (es) 2012-05-30
HRP20140157T1 (hr) 2014-03-28
RU2016125895A (ru) 2018-12-05
CO6511249A2 (es) 2012-08-31
US20150150889A1 (en) 2015-06-04
BR112012005044A2 (pt) 2016-05-03
RS53202B (sr) 2014-06-30
SI2488170T1 (sl) 2014-04-30

Similar Documents

Publication Publication Date Title
MA33743B1 (fr) Compositions comprenant du tramadol et du célécoxib dans le traitement de la douleur
MA32397B1 (fr) Agonistes mixtes basés sur gip destinés au traitement de troubles métaboliques et de l'obésité
MA32099B1 (fr) Composition comprenant un anticorps se liant au domaine ii de her2 et variantes acides de celle-ci
MA38144A1 (fr) Compositions et procédés pour le traitement de protéinopathies
MA37963A1 (fr) Protéines de fusion pour traiter un syndrome métabolique
MA35458B1 (fr) Variants du facteur de croissance des fibroblastes 21
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
EA200802166A1 (ru) Стабильная фармацевтическая композиция с защитным действием от раздражения (варианты), способ ее получения и способ лечения кальций-миметиком с ее помощью
BR112015007985A8 (pt) uso do carboidrato galactose denteada para preparação de composições para tratamento de nefropatia diabética e de distúrbios associados, e suas composições
MA32132B1 (fr) Utilisation de ranolazine pour traiter la douleur
FR3028753B1 (fr) Gel aqueux ou hydroalcoolique de phyllosilicates synthetiques a titre d'agent viscosant, matifiant et/ou homogeneisant d'application
SG178948A1 (en) Fatty acid niacin conjugates and their uses
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
MA34555B1 (fr) Nouvelles protéines de liaison à un antigène
MX2011000255A (es) Combinacion de un antagonista a c-met y un compuesto aminoheteroarilo, para el tratamiento de cancer.
MY167918A (en) Composition for use in the sublingual delivery of medicaments to humans
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
MA50406B1 (fr) Inhibiteurs pyrazole de magl
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
FR2918988B1 (fr) Extrait polysaccharidique de lentinus et compositions pharmaceutiques, cosmetiques ou nutraceutiques comprenant un tel extrait.
FR2913885B1 (fr) Utilisation de la citrulline pour le traitement des pathologies liees a une augmentation de la carbonylation des proteines